1、White Paper on Circular Economy2 The European Commissions Circular Economy Action Plan1,their Roadmap2 and the European Green Deal3 have established direction for the future approach to a sustainable business model based on circularity.Transitioning to a more circular economy requires changes throug

2、hout value chains,from product design,manufacturing and supply,to new business and market models.Designing products for low environmental impacts,identifying new ways of turning waste into resources,prolonging the life of products and changes to consumer behaviour are also important considerations.E

3、FPIA,the research-based pharmaceutical industry is supportive of the principles of the Circular Economy Action Plan and sees synergies with our aspiration to safeguard the future supply of pharmaceuticals for patients and improve human health.Implementation of a circular economy is fundamental to he

4、lp limit global warming4 and we welcome the opportunity to be part of the solution by working collaboratively with the EU in shaping the legislative framework and within our organizations to mitigate our impacts.1 The European Commission,2020 Circular Economy Action Plan https:/ec.europa.eu/environm

5、ent/circular-economy/pdf/new_circular_economy_action_ plan.pdf2 The European Commission,2019,Annex-Roadmap and key actions https:/ec.europa.eu/info/files/annex-roadmap-and-key-actions_en3 The European Commission,2020,Communication on The European Green Deal https:/ec.europa.eu/info/files/communicati

6、on-european-green-deal_en4 United Nations,2015,Paris Agreement http:/unfccc.int/files/essential_background/convention/application/pdf/english_paris_agreement.pdf5 https:/www.sustainable-markets.org/taskforces/health-systems-taskforce/The pharmaceutical industrys approach to circularity builds on eff